Paliperidone



Paliperidone





(pal ah peer’ ah dohn)

InvegaDNC, Invega Sustenna

PREGNANCY CATEGORY C


Drug Classes

Atypical antipsychotic

Benzisoxazole


Therapeutic Actions

Mechanism of action not completely understood; is the major active metabolite of risperidone. Blocks dopamine and serotonin receptors in the brain and depresses the RAS. Antihistaminic and alpha-adrenergic blocking activity may contribute to some therapeutic and adverse effects.


Indications



  • Treatment of schizophrenia; acute and long-term maintenance treatment of schizophrenia; as monotherapy or as adjunct to mood stabilizers or antidepressants in patients 12 yr and older


  • Acute treatment of schizoaffective disorder as monotherapy or with antidepressant or mood stabilizers (oral only)


  • NEW INDICATION: Unlabeled use: Psychoses or agitation related to Alzheimer’s disease



Available Forms

ER tabletsDNC—1.5, 3, 6, 9 mg; injection—39/0.25 mL, 78 mg/0.25 mL, 117 mg/0.75 mL, 156 mg/mL, 234 mg/1.5 mL


Dosages

Adults



  • Schizophrenia and schizoaffective disorder: 6 mg/day PO in the morning; may be adjusted to a maximum 12 mg/day PO if warranted and tolerated by the patient. Increases of 3 mg/day at intervals of at least 4 days are suggested.


  • Schizophrenia: Parenteral—234 mg IM, followed by 156 mg IM in 1 wk, both injections in the deltoid. 117 mg IM 1 wk later in gluteal or deltoid site. Maintenance dose—39–234 mg IM once per month in deltoid or gluteal site.

Pediatric patients 12–17 yr



  • Treatment of schizophrenia: Weighing 51 kg and more: Initially, 3 mg/day PO; range, 3–12 mg/day.



    • Weighing less than 51 kg: Initially, 3 mg/day PO; range, 3–6 mg/day.

Patients with renal impairment

Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Jul 21, 2016 | Posted by in NURSING | Comments Off on Paliperidone

Full access? Get Clinical Tree

Get Clinical Tree app for offline access